Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a current diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders Version IV (DSM-IV)~* Must be admitted to a hospital within 4 weeks prior to Screening experiencing an acute exacerbation of schizophrenia~* Have a positive and negative syndrome scale (PANSS) total score of more than or equal to 60 or clinical global impressions - severity (CGI-S) score of more than or equal to 4 (moderately ill) at Screening~* Agree to protocol-defined method of contraception~* Must be medically stable based on physical examination, medical history, vital signs, and clinical laboratory tests performed at Screening~Exclusion Criteria:~* Have a primary active DSM-IV Axis I diagnosis other than schizophrenia~* Have evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal, neurological, endocrine, metabolic or pulmonary disease in medical history, clinical laboratory or physical examination~* Have a history of neuroleptic malignant syndrome~* Participants at risk of suicide~* Have received clozapine within 1 month prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Paliperidone palmitate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).